Paired box gene 8, HBME‐1, and cytokeratin 19 expression in preoperative fine‐needle aspiration of papillary thyroid carcinoma

Paired box gene 8 (PAX8), a member of the thyroid‐specific transcription factors, has recently been investigated as a useful marker of thyroid epithelial neoplasms. To the authors' knowledge, its utility in the immunohistochemistry of papillary thyroid carcinoma (PTC) has not been well studied to date. The goal of the current study was to compare the immunohistochemical expression of PAX8 with HBME‐1 and cytokeratin 19 (CK19) expression on cell block preparations of PTC and benign thyroid nodules (BTN).

[1]  Jining Feng,et al.  Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy , 2009, CytoJournal.

[2]  M. Nga,et al.  HBME‐1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma , 2008, Diagnostic cytopathology.

[3]  M. Rivera,et al.  Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms , 2008, Modern Pathology.

[4]  S. Kwak,et al.  Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the Differential Diagnosis of Thyroid Nodules , 2007, Journal of Korean medical science.

[5]  M. Bouchard,et al.  Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. , 2007, Journal of the American Society of Nephrology : JASN.

[6]  N. Bowen,et al.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. , 2007, Gynecologic oncology.

[7]  S. Mukhopadhyay,et al.  Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining , 2006, Modern Pathology.

[8]  Yao-Tseng Chen,et al.  Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. , 2006, American journal of clinical pathology.

[9]  C. Lombardi,et al.  Simultaneous immunohistochemical expression of HBME‐1 and galectin‐3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid , 2006, Histopathology.

[10]  Ping Zhang,et al.  Immunohistochemical analysis of thyroid‐specific transcription factors in thyroid tumors , 2006, Pathology international.

[11]  J. Bidart,et al.  PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. , 2004, European journal of endocrinology.

[12]  T. Fahey,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .

[13]  C. Cheung,et al.  Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.

[14]  L. Weiss,et al.  Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. , 1992, Human pathology.

[15]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[16]  S. Asa.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid , 2005, Endocrine pathology.

[17]  H. Nagaraja,et al.  Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.

[18]  A. Renshaw,et al.  Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma. , 2002, American journal of clinical pathology.